


Synonym

LYPD1, Ly6/PLAUR domain-containing protein 1, FLJ41033, LY6/PLAUR domain containing 1, LYPDC1, PHTS, Putative HeLa tumor suppressor

Source

Biotinylated Human LYPD1 Protein, His,Avitag(LY1-H82E6) is expressed from human 293 cells (HEK293). It contains AA Leu 21 - Gly 115 (Accession # [Q8N2G4-1](#)).

Molecular Characterization



This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™)

The protein has a calculated MW of 14.1 kDa. The protein migrates as 18-22 kDa and 35-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Labeling

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Protein Ratio

Passed as determined by the HABA assay / binding ELISA.

Endotoxin

Less than 1.0 EU per µg by the LAL method.

Purity

>90% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 µm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE



Biotinylated Human LYPD1 Protein, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

Bioactivity-ELISA

LYPD1 ELISA

Immobilized Biotinylated Human LYPD1 Protein, His,Avitag (Cat. No. LY1-H82E6) at 1 µg/mL (100 µL/well) on streptavidin precoated (0.5 µg/well) plate

can bind Anti-LYPD1 antibody with a linear range of 0.008-0.125 µg/mL (QC tested).

Background

Believed to act as a modulator of nicotinic acetylcholine receptors (nAChRs) activity. In vitro increases receptor desensitization and decreases affinity for ACh of alpha-4:beta-2-containing nAChRs. May play a role in the intracellular trafficking of alpha-4:beta-2 and alpha-7-containing nAChRs and may inhibit their expression at the cell surface. May be involved in the control of anxiety.

Clinical and Translational Updates

Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.